DWA
CLSD

Dorsey Wright & Associates’s Clearside Biomedical CLSD Stock Holding History

Dorsey Wright & Associates’s Portfolio CLSD Stock Details CLSD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-602
Closed -$54K – 288
2021
Q3 		$54K Buy
+602
New +$53.1K 0.01% 188

Other funds holding CLSD

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $127M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dorsey Wright & Associates's CLSD Position: Q4 2021 in Review

Dorsey Wright & Associates sold out of Clearside Biomedical (CLSD) in Q4 2021, closing a stake of 602 shares — an estimated $54K sold.

Dorsey Wright & Associates first reported a position in CLSD in Q3 2021 and held it in 1 quarter. The position peaked at $54K in Q3 2021. 67 funds tracked by Wall St. Rank hold CLSD as of Q4 2021.

  • Dorsey Wright & Associates reported no remaining Clearside Biomedical position as of Q4 2021 after selling out during the quarter.
  • Dorsey Wright & Associates sold 602 Clearside Biomedical shares in Q4 2021, an estimated $54K.
  • Dorsey Wright & Associates first reported a position in Clearside Biomedical in Q3 2021 and held it in 1 quarter.
  • Dorsey Wright & Associates's Clearside Biomedical position peaked at $54K in Q3 2021.
  • 67 funds tracked by Wall St. Rank held Clearside Biomedical as of Q4 2021.

Based on Dorsey Wright & Associates's 13F filing for Q4 2021, filed 27 Jan 2022.